This article is more than 5 years old. Information may no longer be current.

Valeant Canada relocates US production of Jublia from Tokyo to Quebec

Valeant Canada announced in a press release that Valeant’s Laval, Quebec-based plant will become the North American production site for Jublia.

Jublia (efinaconazole 10%) is a prescription-based topical triazole antifungal agent developed for toenail fungus, according to the release. Eighty percent of Jublia volume is based on the U.S. production, which was previously manufactured in Tokyo and packaged in the U.S., the release reported.

“As we take on the role of global production center for prescription dermatology products, this now world-class facility allows us to become a major player in our industry at home and abroad,” Jacque Dessureault, president and general manager of Valeant Canada, stated in the release.

The relocation of the production to the Laval plant has included an investment in more than $1 million, including changes to the medication’s packaging, construction of specialized rooms used to manipulate ethanol and improved flammable safety storage units, according to the release.

Reference: www.valeantcanada.com